-+ 0.00%
-+ 0.00%
-+ 0.00%

KEROS THERAPEUTICS ANNOUNCES THE FIRST PATIENT DOSING IN THE PHASE 2 CLINICAL TRIAL EVALUATING RINVATERCEPT IN DMD

Reuters·09/28/2026 12:00:03

Please log in to view news